Market Cap 1.01B
Revenue (ttm) 297.20M
Net Income (ttm) -11.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.98%
Debt to Equity Ratio 0.02
Volume 12,300
Avg Vol 12,536
Day's Range N/A - N/A
Shares Out 68.52M
Stochastic %K 30%
Beta 0.04
Analysts Strong Sell
Price Target $30.67

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 71 524 7400
Fax: 31 71 524 7445
Address:
Darwinweg 24, Leiden, Netherlands
Gabriel1234
Gabriel1234 Oct. 23 at 7:09 PM
$PHAR https://www.marketwatch.com/investing/stock/phar
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:57 PM
$PHAR Positive results highlighted: The press release specifically mentions “positive new clinical, economic, and comparative data” — implying that results are favorable and could support stronger positioning versus competitors (e.g., Sebetralstat for HAE). Broader awareness: Presenting at ACAAI boosts visibility among specialists, potentially helping future prescriptions and market adoption for both drugs. Long-term signal: It strengthens Pharming’s reputation in rare disease research, which could attract new partnerships or clinical collaborations.
1 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:56 PM
$PHAR Scientific recognition: Having 12 abstracts accepted at a major international conference (ACAAI 2025) demonstrates strong recognition of Pharming’s research quality and scientific credibility in rare diseases. Pipeline strength: The data covers both of Pharming’s marketed drugs — RUCONEST®, already approved for hereditary angioedema (HAE) Joenja® (leniolisib), approved for APDS — and shows ongoing clinical, real-world, and economic research, suggesting continued development and relevance.
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:55 PM
$PHAR Pharming Group N.V. announced that 12 scientific abstracts have been accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida (November 6–10, 2025). Five posters will share new data on RUCONEST® for the on-demand treatment of hereditary angioedema (HAE), while seven focus on Joenja® (leniolisib) and its real-world effectiveness in treating APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome). The studies highlight clinical outcomes, cost-effectiveness, quality of life, and patient/caregiver experiences.Pharming’s Chief Medical Officer, Anurag Relan, emphasized that these presentations reflect the company’s commitment to advancing care for patients with rare diseases.
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 1:55 PM
$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio-07005207?mod=mw_quote_news_seemore
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 20 at 10:02 AM
WATCHLIST OCT 20 2025 $NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event $SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study $IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance $PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases $STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications
0 · Reply
Ruconestor
Ruconestor Oct. 15 at 3:26 PM
$PHAR IEX vol vieze kleine tradertjes:) MSAM 15 oktober 2025 15:54 auteur info Ondanks alle hosannakoersperpectieven: nu kun je ze nog voor € 1,20 verkopen. De komende dagen week niet meer. En dan wachten op de Q3-resultaten
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 4:03 PM
$PHAR 11:41 on Oct. 06 2025 Pharming Group Announces Restructuring With 20% Headcount Reduction To Cut Costs By $10M Annually; Anticipates One-Time Restructuring Costs Of ~$7M To Be Recorded In Q4 2025 In Connection With The Headcount Reduction #tradeideas
0 · Reply
Noobnr1
Noobnr1 Oct. 6 at 6:40 AM
$NYXH Succes in Texas with thier Genio-system🥂💤🚀 $PHAR $GILD $DVAX $PFE
0 · Reply
Ruconestor
Ruconestor Oct. 3 at 9:49 AM
0 · Reply
Latest News on PHAR
Pharming Group promoted to the Euronext AMX® index

Sep 10, 2025, 1:00 AM EDT - 6 weeks ago

Pharming Group promoted to the Euronext AMX® index


Pharming Group to participate in August investor conference

Aug 4, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to participate in August investor conference


Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 3:04 PM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript


Pharming Group to participate in June investor conferences

May 28, 2025, 2:00 AM EDT - 5 months ago

Pharming Group to participate in June investor conferences


Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:50 AM EDT - 6 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript


Pharming Group to participate in April investor conferences

Mar 28, 2025, 3:00 AM EDT - 7 months ago

Pharming Group to participate in April investor conferences


Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:44 PM EDT - 8 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript


Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:44 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript


Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript


Pharming Group to participate in May investor conference

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference


Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript


Gabriel1234
Gabriel1234 Oct. 23 at 7:09 PM
$PHAR https://www.marketwatch.com/investing/stock/phar
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:57 PM
$PHAR Positive results highlighted: The press release specifically mentions “positive new clinical, economic, and comparative data” — implying that results are favorable and could support stronger positioning versus competitors (e.g., Sebetralstat for HAE). Broader awareness: Presenting at ACAAI boosts visibility among specialists, potentially helping future prescriptions and market adoption for both drugs. Long-term signal: It strengthens Pharming’s reputation in rare disease research, which could attract new partnerships or clinical collaborations.
1 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:56 PM
$PHAR Scientific recognition: Having 12 abstracts accepted at a major international conference (ACAAI 2025) demonstrates strong recognition of Pharming’s research quality and scientific credibility in rare diseases. Pipeline strength: The data covers both of Pharming’s marketed drugs — RUCONEST®, already approved for hereditary angioedema (HAE) Joenja® (leniolisib), approved for APDS — and shows ongoing clinical, real-world, and economic research, suggesting continued development and relevance.
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 9:55 PM
$PHAR Pharming Group N.V. announced that 12 scientific abstracts have been accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida (November 6–10, 2025). Five posters will share new data on RUCONEST® for the on-demand treatment of hereditary angioedema (HAE), while seven focus on Joenja® (leniolisib) and its real-world effectiveness in treating APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome). The studies highlight clinical outcomes, cost-effectiveness, quality of life, and patient/caregiver experiences.Pharming’s Chief Medical Officer, Anurag Relan, emphasized that these presentations reflect the company’s commitment to advancing care for patients with rare diseases.
0 · Reply
Gabriel1234
Gabriel1234 Oct. 20 at 1:55 PM
$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio-07005207?mod=mw_quote_news_seemore
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 20 at 10:02 AM
WATCHLIST OCT 20 2025 $NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event $SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study $IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance $PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases $STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications
0 · Reply
Ruconestor
Ruconestor Oct. 15 at 3:26 PM
$PHAR IEX vol vieze kleine tradertjes:) MSAM 15 oktober 2025 15:54 auteur info Ondanks alle hosannakoersperpectieven: nu kun je ze nog voor € 1,20 verkopen. De komende dagen week niet meer. En dan wachten op de Q3-resultaten
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 4:03 PM
$PHAR 11:41 on Oct. 06 2025 Pharming Group Announces Restructuring With 20% Headcount Reduction To Cut Costs By $10M Annually; Anticipates One-Time Restructuring Costs Of ~$7M To Be Recorded In Q4 2025 In Connection With The Headcount Reduction #tradeideas
0 · Reply
Noobnr1
Noobnr1 Oct. 6 at 6:40 AM
$NYXH Succes in Texas with thier Genio-system🥂💤🚀 $PHAR $GILD $DVAX $PFE
0 · Reply
Ruconestor
Ruconestor Oct. 3 at 9:49 AM
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:21 AM
$PHAR Excellent article that nails exactly where PHAR stands right now. So if you want to update your PHAR knowledge or get acquainted with PHAR, this is a must read. https://beyondspx.com/quote/PHAR/analysis/pharming-s-dual-growth-engines-and-pipeline-propel-rare-disease-leadership-nasdaq-phar
0 · Reply
Ruconestor
Ruconestor Oct. 1 at 2:57 PM
$PHAR Aandeel gaat verder knallen. Eindelijk valt alles op z'n plek. Mooi die veiligheid gebleken zelfs voor kleuters!! Wachten is op de diverse andere indicaties Very strong buy for very safe and curing Medicins 👍
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 1 at 12:33 PM
$PHAR (+2.1% pre) Pharming shares up as FDA grants priority review for Joenja in children https://ooc.bz/l/79027
0 · Reply
Gabriel1234
Gabriel1234 Oct. 1 at 11:13 AM
$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years-1c5a7bca?mod=mw_quote_news_seemore
0 · Reply
Noobnr1
Noobnr1 Oct. 1 at 9:19 AM
$NYXH it’s will be a huge company soon 🚀 $GILD $PFE $PHAR Fast judgement by FDA = approval very soon 🥳🥳
0 · Reply
Longterm007
Longterm007 Oct. 1 at 6:14 AM
$PHAR News: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years https://www.pharming.com/news/pharming-group-announces-us-fda-acceptance-priority-review-supplemental-new-drug-application-leniolisib-pediatric-APDS
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Sep. 29 at 10:41 AM
$PHAR Recovery from 100% tariff scare.
0 · Reply
Longterm007
Longterm007 Sep. 26 at 12:25 PM
$PHAR Fuck Trump
0 · Reply
ap20
ap20 Sep. 26 at 11:28 AM
$PHAR Added early in the US.
0 · Reply
Ruconestor
Ruconestor Sep. 26 at 8:36 AM
$PHAR Irish Trade Minister Harris States EU-US Trade Deal Keeps Pharma Tariffs at 15%, Emphasizes Importance of Agreement
0 · Reply
Ruconestor
Ruconestor Sep. 23 at 12:26 PM
$PHAR Organisatiepagina weergeven voor Pharming Group. Pharming Group 14.072 volgers 1 w 📢 We're proud to share that we've been promoted to the Euronext AMX Index. This promotion reflects our strong growth momentum and recognition in the market. It’s a meaningful step that enhances our visibility and further strengthens our profile, especially with the investor community. A big thank you to our team and partners for helping us reach this milestone, and to our investors for their continued confidence 🤝. 👉 Read more: https://bit.ly/3VFcAH4
0 · Reply
ap20
ap20 Sep. 14 at 6:54 PM
$PHAR OK European team: hoping your index boys will step up this week to own some PHAR. And good luck to your Ryder Cup team. I have read about the sportsmanship and comradery way back when the matches started. I wish it could get back that way…
0 · Reply